Accrufer/Feraccru filed in Canada to treat to treat iron deficiency anaemia.
Shield Therapeutics plc with its lead product Accrufer/Feraccru (ferric maltol), announces that KYE Pharmaceuticals Inc. (‘KYE’) has submitted a New Drug Submission (‘NDS’) to Health Canada for the regulatory review and approval of Accrufer.
If approved, Accrufer would be the first prescription only oral iron therapy approved by Health Canada. Marketing approval for Accrufer is expected to be during first half of 2023.
Related news and insights
Palisade Bio, Inc. announced the first patient has been dosed in its Phase III study evaluating LB 1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery.
bluebird bio, Inc. announced the FDA has approved Zynteglo (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta-thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions.
Edwards Lifesciences Corporation announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the treatment of mitral and tricuspid regurgitation (MR and TR).